60results about "Chlorine active ingredients" patented technology

Provided is a method for producing a chlorous acid water preparation in which chlorous acid water, chlorous acid as a main effective component thereof, and chlorine peroxide radicals as active molecular species thereof have been more efficiently stabilized in the liquid at ordinary temperature in high and low concentrations. The method is for producing a chlorous acid water preparation having a predetermined content (in terms of chlorous acid (HClO2=68.46)), and comprises: (1) preparing a buffer solution; (2) obtaining the concentration of the buffer solution; (3) preparing chlorous acid water; (4) obtaining a content in the chlorous acid water (in terms of chlorous acid (HClO2=68.46)); (5) obtaining an amount of the buffer solution required for dilution, from the content in the chlorous acid water (in terms of chlorous acid (HClO2=68.46)) and the predetermined content (in terms of chlorous acid (HClO2=68.46)); and (6) diluting the chlorous acid water with said amount of the buffer solution to produce a chlorous acid water preparation having the predetermined content (in terms of chlorous acid (HClO2=68.46)).

Provided are anti-microbial compositions that include an aqueous solution of hypochlorous acid encapsulated in a nanoparticle that allows for controlled release of hypochlorous acid. Also provided are methods of making and using such compositions.

The invention discloses blood filtration replacement liquid as well as a preparation method and application thereof. The displacement liquid comprises low molecular weight heparin calcium, prostaglandin E1, prostacyclin, electrolyte with specific concentration, glucose and an interleukin-1 receptor antagonist. The preparation method comprises the following steps: weighing the raw materials according to the proportion, dissolving to a constant volume, removing pyrogen and heat, and carrying out aseptic packaging. During clinical application, replacement liquid and blood are filtered according to the replacement rate of 1: 1-2: 1 according to the condition of a patient, 4-6 hours each time and 2-3 times each week, and related indexes are monitored. Animal tests show that the replacement liquid has good safety under the effective dosage, and has potential influence on part of organs under the high dosage. A stability test shows that the compound can be stably stored under a certain condition. The invention provides the replacement liquid which can achieve anticoagulation and blood vessel protection, maintain electrolyte balance and relieve inflammatory response, is expected to improve the prognosis of hemodialysis patients, and has important clinical significance and wide application prospects.

Disclosed herein are methods for making compositions stably comprising one or more peroxides and one or more free available chlorine species, one or more peroxides for use in making compositions stably comprising one or more peroxides and one or more free available chlorine species, and compositions formulated using compositions made according to the methods or uses disclosed herein.

This invention relates to the field of biomedicine and hygiene disinfection products technology, and discloses a method for preparing a slightly acidic oxidizing potential hydrogel. The gel is made from slightly acidic oxidizing potential water and an inorganic gelling agent, lithium magnesium silicate. The preparation method includes: separately preparing strongly acidic oxidizing potential water and alkaline reducing potential water by electrolysis; mixing the two online in a preset ratio; adjusting the pH value to 5.0 to 6.5 through a neutralization reaction; subsequently adding lithium magnesium silicate; and then dispersing the mixture through high-speed shearing and sealing for static swelling to form a gel. This invention solves the problems of easy decomposition of available chlorine and gel liquefaction by utilizing an inorganic gel system, resulting in a gel with high stability and a long shelf life. This product solves the problem of easy loss of liquid disinfectants, prolongs the bactericidal effect time on wounds and oral ulcers, and is non-irritating and non-sensitizing to the skin, making it suitable for long-term disinfection of hands, skin, and mucous membranes.

To provide a coronavirus killing agent.SOLUTION: The present disclosure provides coronavirus killing agents. In particular, the present disclosure provides a coronavirus disinfectant comprising a chlorous acid aqueous solution. In particular, the present disclosure provides a method for killing or disinfecting coronavirus using a chlorous acid aqueous solution. The concentration of free chlorine (assuming Cl = 35.45) in a chlorous acid aqueous solution can be at least 5ppm or higher in the absence of organic matter. The content of chlorous acid in the chlorous acid aqueous solution (HClO2 = 68.46) can be at least 200ppm or more under the presence of organic matter including disinfection of hands and the like. The coronavirus may be SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV), or 2019 novel coronavirus (SARS-CoV-2).SELECTED DRAWING: None

Provided are anti-microbial compositions that include an aqueous solution of hypochlorous acid encapsulated in a nanoparticle that allows for controlled release of hypochlorous acid. Also provided are methods of making and using such compositions.

A method of monitoring and treating a subject with ALS based on biomarkers. In some embodiments, the method comprises: identifying that a subject has a ratio of LPS1EGF associated with ALS; and based on the identifying that the subject has the ratio of LPS:EGF associated with ALS, determining that the subject is eligible for sodium chlorite therapy for the ALS, determining based on the ratio of LPS:EGF whether to continue the therapeutic regimen of sodium chlorite; wherein the ratio of LPS:EGF in the subject is no greater than 50 and the therapeutic regimen of sodium chlorite is about 0.2 mg / kg / day to about 3.5 mg / kg / day administered orally and / or parenterally.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Q), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

Described is a method for treating or preventing an infection, such as an infection associated with Staphylococcus epidermidis such as a Health-Care Associated infection, a wound, a sore, an ulcer, a burn. The method includes applying a treatment preparation to a treatment site, the treatment preparation has a first component having a single amino acid, said single amino acid being leucine, and a second component having an active chlorine compound.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

Described herein are method and kits for locally treating or preventing infection in a patient in need thereof. The method may include locally administering to a human patient a plurality of doses of at least one antiseptic agent in solution by irrigating the at least one antiseptic agent at a wound, wherein the administration provides the patient continuous localized antiseptic therapy for at least a 24-hour period, at least 48-hour period, at least a 72-hour period, or at least a 96-hour period.

Methods for treating or preventing ulcers caused by Epidermolysis Bullosa (“EB”), EGFR inhibitor-induced skin toxicities, lesions caused by Hailey-Hailey Disease (“HHD”), Buruli Ulcers, and SARS-CoV-2 infections, by topically applying a hypotonic, acid oxidizing solution containing hypochlorous acid (HClO) to the affected area.

A composition for lubricant formulations is disclosed. The composition may include hypochlorite, dimethicone, and an emulsifier for improvement of lubricity. Methods of making and using the lubricant formulations are also disclosed.

To provide a new method capable of easily sterilizing spores with high safety.SOLUTION: A radical manufacturing method includes a treatment step of irradiating a radical generating source with light, generating a radical, and treating spores with the radical, wherein a peak wavelength of the irradiation light in the light irradiation exceeds a UV wavelength and is 600 nm or less. A spore sterilization method includes a treatment step of irradiating a radical generating source with light, generating a radical, and treating spores with the radical, wherein a peak wavelength of the irradiation light in the light irradiation exceeds a UV wavelength and is 600 nm or less. The peak wavelength is, for example, 405 to 470 nm.SELECTED DRAWING: None

The present specification discloses a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine in combination with one or more quaternary compounds or silicon quaternary compounds, one or more guanide-containing compounds, one or more alcohols, one or more metallic particles, one or more metal salts, or any combination thereof. The present specification further discloses a kit comprising, consisting essentially of, or consisting of a one or more containers including a composition disclosed herein or components which make up such compositions as well as methods and uses for such compositions and kits.

A hypochlorous acid-containing composition for treating and preventing onychomycosis, which composition comprises about 1 to 50,000 ppm of hypochlorous acid; a pH adjusting agent to adjust the pH of the composition to 2 to 9; and water. The hypochlorous acid can inhibit or kill Trichophyton rubrum, Candida albicans, Fusarium spp., Aspergillus spp., Acremonium spp., Scytalidium spp., and Scopulariopsis brevicaulis, as well as other fungal strains and spores thereof that pose a potential risk of causing onychomycosis. Therefore, the hypochlorous acid effectively eliminates fungi, spores and other pathogens that cause onychomycosis in infected nails, thus preventing the recurrence of onychomycosis. This provides a thorough solution for patients and offers the general public (including patients) an effective method to prevent the development of onychomycosis before the onset of symptoms.

Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided for treating biofilms without inducing antimicrobial resistance.

According to the present invention, provided is a Clostridium perfringens sporulation inhibitor that contains at least one inorganic compound at such a concentration as to cause the precipitation of C. perfringens in vivo, wherein the inorganic compound is a salt of at least one selected from the group consisting of K, Na, Mg, Ca and Fe and the inorganic compound is coated with a protective layer containing a hardened vegetable oil.

The application provides application of bipolar water antibacterial liquid in preparation of a medicine for preventing and / or treating skin fungi, and belongs to the technical field of biological medicine preparation. The application evaluates the in-vivo antibacterial activity of the bipolar water on fungal pathogenic bacteria by constructing a mouse model of trauma infection, and research finds that after treatment by the bipolar water, the load of Cryptococcus neoformans, Candida auris, Malassezia, Microsporon canis, Trichophyton mentagrophytes, Rhizopus microsporus, Trichophyton rubrum and Cryptococcus gattii can be effectively removed, the infection symptoms can be effectively improved, and wound healing can be promoted, so that the purpose of preventing and / or treating skin fungi or skin fungal infectious diseases is achieved, and a theoretical basis for clinical application value of the bipolar water on pathogenic bacteria is provided.

The invention generally relates to compositions of hypochlorous acid (HOCl) and methods of manufacture thereof. In certain aspects, the invention provides air-free compositions of HOCl. In other aspects, the invention provides methods of making HOCl that involve mixing together in water in an air-free environment, a compound that generates a proton (H+) in water and a compound that generates a hypochlorite anion (OCl−) in water to thereby produce air-free hypochlorous acid.

This invention discloses a plasma-activated silver nanogel, its preparation method, and its application. The preparation method includes the following steps: S1, mixing silver nanoparticles with agarose solution, heating and reacting, and then allowing it to stand until it becomes a gel; S2, immersing the gel obtained in S1 in physiological saline; S3, subjecting the gel treated in S2 to plasma treatment to obtain the plasma-activated silver nanogel. The method of this invention locks the active particles in the gel before applying it to the skin surface, avoiding direct or close-range contact between the plasma generator and the skin, thus preventing skin burns and ensuring safety. Simultaneously, it synergistically enhances the effects of silver ions and ClO₂. ‑ It has a dual antibacterial mechanism, which relieves redness, swelling, and thickened scales, accelerates the resolution of inflammation, regulates the immune response, and relieves symptoms of chronic inflammatory diseases (such as psoriasis).

Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided for treating biofilms without inducing antimicrobial resistance.

To provide human milk compositions and methods of making and using the same.SOLUTION: In particular, the disclosure features methods of using human milk compositions to feed subjects before and / or after surgery or medical operations and that are useful in promoting recovery.SELECTED DRAWING: None

An apparatus and method for inactivating infectious organisms in human body are provided. The apparatus comprises a body having an elongated balloon shape with an open end; a disinfectant containing chlorine dioxide accepted in the body; and an activation module coupled to the body, the activation module includes a case having an opening capable of accommodating the body, an energy supply unit for supplying energy to the disinfectant to activate the chlorine dioxide and a controller for controlling the energy supply unit. The method comprises the steps of inserting the device into a vagina and controlling a degree of activation of the chlorine dioxide to inactive infectious organisms in the vagina by adjusting an intensity of the energy.

Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating transient biofilms in or on tissue without harming the natural flora of the tissue. The compositions are useful for treating a variety of types of tissue. Compositions are useful for treating and preventing orally-associated biofilm. Compositions may be provided in mouthwash form, spray form, gel form, cream form, dentifrice form, and may include nanoparticle encapsulated molecules for controlled release.

The present invention provides new storable and stable disinfectant compositions comprising use of a solid precursor of an oxidized state of chlorine. The component in the device is devoid of stability issues, since the solid precursors are instantly to be dissolved in water or a pharmaceutically acceptable diluent, adjuvant, or carrier, and combined with an activator, e.g. adipic or succinic acid or their salts, optionally combined with a viscosity enhancer, optionally combined with a dye. The main product according to the invention is generated by dissolving effervescent material in the form of tablets or granules, the resulting solutions from dissolution of the effervescent material are useful disinfectants for treating a broad spectrum of pathogenic bacterial and / or viral, fungal, or parasitic pathogens, denoted microbials.

Provided are antimicrobial compositions for wound management and methods of producing the antimicrobial compositions, comprising sodium hypochlorite (NaOCl) in an amount ranging from 0.015 to 0.15% by weight, hypochlorous acid (HOCl) in an amount ranging from 0.002 to 0.1% by weight, a synthetic silicate clay-based thickener in an amount ranging from 1 to 10% by weight, sodium chloride (NaCl) in an amount ranging from 0.03 to 0.3% by weight, and purified water, wherein the purified water prior to addition to the composition has a hardness of less than 5 ppm as measured according to ISO 15923-2:2017 and a resistivity of greater than 15 MΩ / cm as measured according to ISO 3696:1987, and the composition has a pH in the range of 7.5 to 10.0, and a buffer capacity β measured at pH 8.0 of 0.15 or less.

A method for monitoring and treating a subject having ALS based on a biomarker. In some embodiments, the method comprises identifying that the subject has a ratio of LPS1EGF associated with ALS; and based on the identification that the subject has a ratio of LPS:EGF associated with ALS, determining that the subject is eligible for sodium chlorite treatment for ALS, determining whether to continue a treatment regimen of sodium chlorite based on the ratio of LPS:EGF; wherein the ratio of LPS:EGF in the subject is 50 or less, and the treatment regimen of sodium chlorite is from about 0.2 mg / kg / day to about 3.5 mg / kg / day administered orally and / or parenterally.